US FDA approves Ability sNDA for irritability associated with autistic disorder in children
Wednesday, November 25, 2009 12:00 IST Princeton, New Jersey
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co, Ltd announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Abilify (aripiprazole)
